MSN Labs launches a new drug for percutaneous coronary intervention

MSN Laboratories, one of country’s leading, fully integrated research-based Pharmaceutical organizations with expertise spanning across the domains of APIs, Finished Dosages and Branded Generics (Prescription Medicines) became the first company to launch the generic CANREALTM injection (Cangrelor) in India.

The bioequivalent generic CANREALTM (Cangrelor) is the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition developed to overcome both delayed and prolonged anti platelet activity. The drug was approved by DCGI (Drug Controller General of India) recognizing the unmet need for intravenous rapidly acting, reversible antiplatelet agent in the country. It is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor

The launch of the product coincided with a mega cardiology CME organized by MSN Labs to commemorate World Heart Day in Hyderabad where Dr Deepak Bhatt, principal investigator of CHAMPION TRIAL and a few of country’s leading cardiologists illumined the audience with their insightful presentations on “ Antiplatelet Therapy Featuring Cangrelor P2Y12 Inhibitor”. The event was attended by over 3,000 cardiologists from all over India.

MSN Group commented: “This launch signifies MSN Labs’ commitment to bring access to new, affordable and diverse therapeutic options, swiftly and consistently, for helping the world overcome life-threatening diseases.  The organization is hopeful that this drug will prove to be highly advantageous for both patients and medical fraternity in terms of treatment outcomes, safety and efficacy.”

The product which comes in a single-use 10 mL vial containing 50 mg Cangrelor as a lyophilized powder for reconstitution, is manufactured at FDA and EU approved state-of-the-art injectable facility in Hyderabad. It is available at all retail/hospital attached pharmaceutical outlets and is dispensed upon a prescription by a cardiologist.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button